California Court’s Landmark Ruling on Gilead Sciences Raises Corporate Governance Concerns

The January ruling from the Court of Appeal of the State of California, First Appellate District, in Gilead Sciences Inc. v. Superior Court of the City and County of San Francisco, has sparked considerable debate within legal circles. The court determined that Gilead Sciences could be held liable for allegedly delaying the release of a safer HIV drug in order to maximize profits on an existing medication. This decision challenges the established principles of corporate governance and raises substantial implications for the business judgment rule, as explained by Shireen Barday at Pallas. If upheld, the verdict could have far-reaching consequences, potentially increasing liability risks for other companies making decisions based on sound business judgment.